Sector Expert: Ross Macdonald

Cynata Therapeutics Ltd.

Image: Ross Macdonald

Ross Macdonald, Ph.D., managing director and CEO of Cynata Therapeutics, has more than 20 years' experience and a track record of success in pharmaceutical and biotechnology businesses. His career history includes positions as chief executive officer of Hatchtech Pty Ltd, vice president of business development for Sinclair Pharmaceuticals Ltd., a UK-based specialty pharmaceuticals company, vice president of business development for Connetics Corp. of Palo Alto, California, and vice president, corporate development for Stiefel Laboratories Inc., the largest independent dermatology company in the world, acquired by GlaxoSmithKline in 2009. Dr. Macdonald has also served as vice president of research and development of F H Faulding & Co. Ltd. and CEO of Living Cell Technologies Ltd. His other positions have included non-executive director roles at iSonea Ltd., Telesso Technologies Ltd., Hatchtech Pty Ltd. and Relevare Pharmaceuticals Ltd. Dr. Macdonald currently serves as a member of the Investment Committee of UniSeed Management Pty Ltd. Dr. Macdonald holds a Ph.D. in biochemistry from Monash University, a graduate diploma in business administration from Swinburne University, and is a member of the Licensing Executives Society.



Recent Interviews

Delivering the Triple Whammy that Makes Stem Cell Therapies Commercially Viable: Cynata Therapeutics' Ross Macdonald (10/14/15)
PastelStemCells580

Stem cell therapies have been slowed by high production costs, batch-to-batch variability and limited seed material. Ross Macdonald, CEO of Cynata Therapeutics, tells The Life Sciences Report how his company's innovative manufacturing methods can generate robust, consistent and inexpensive stem cells, and how this technology is likely to accelerate the commercialization of stem cell therapies worldwide.



Due to permission requirements, not all quotes are shown.